Skip to main content

Alexus Williams is an associate with the transactional team. Her practice focuses on advising companies on complex contractual relationships and facilitating commercial transactions in the life sciences industry. Ms. Williams assists clients such as pharmaceutical, consumer healthcare, biotech, and medical device companies with transactional, operational, and general corporate matters, including industry specific transactional matters such as licensing agreements, collaboration agreements, clinical trial agreements, CRO agreements, services agreements, informed consent forms, material and technology transfer agreements, manufacturing and supply agreements, distribution agreements, and confidentiality agreements. Ms. Williams also represents clients from a range of industries on matters relating to entity formation, corporate governance, mergers and acquisitions, joint ventures, and collaborations.


  • Novartis in (i) an exclusive license and option agreement with Shanghai Argo Biopharmaceutical (a Chinese biotechnology company) for a Phase 1 stage cardiovascular asset and an option to license compounds directed against up to two cardiovascular targets, and (ii) an ex-Greater China exclusive license agreement with Shanghai Argo Biopharmaceutical for a Phase 1/2a stage cardiovascular asset, for an upfront payment of US$185 million plus potential milestone payments and royalties, with a combined potential deal value of up to US$4.165 billion.
  • LegoChem Biosciences in an exclusive, worldwide license agreement with Janssen on LCB84, a Trop2 directed antibody drug conjugate. LCB and Janssen will collaborate during the ongoing Phase 1/2 clinical trial for LCB84, and then Janssen will be responsible for clinical development and commercialization of LCB84. LCB is eligible for up to US$1.7 billion -- an upfront payment of US$100 million, an option exercise payment of US$200 million, and other milestone payments. LCB will also receive tiered royalties on any net sales.
  • BioNTech in a license and collaboration agreement with MediLink Therapeutics for the development of a next-generation antibody-drug conjugate (ADC) candidate against Human Epidermal Growth Factor Receptor 3 (HER3), with deal value totaling over US$1 billion.



  • J.D., Seton Hall University School of Law, 2019, Presidential Scholarship and Seton Hall Law Review, Comments Editor
  • B.A., Environmental and Business Economics, Rutgers University, 2016, James Dickson Carr Scholarship


  • New Jersey